Received Sep 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | 3CA55C1 | OT / LA |
provider ordered daptacel instead of tdap for an 8 year old patient and it was administered with no adverse event; provider ordered daptacel instead of tdap for an 8 year old patient and it was administered with no adverse event; Initial information received on 16-Sep-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves an 8-year-old male patient who was administered with diphtheria-15/tetanus/5 AC pertussis vaccine [Daptacel] instead of diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (TDAP) due to provider ordering ,with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 08-Sep-2025, the patient of 8 years old received a dose 0.5ml 1x (once) of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE , Suspension for injection (lot 3CA55C1, expiry :31-Aug-2026) via intramuscular route in the left deltoid as immunization instead of DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID produced by unknown manufacturer (lot number, Form and expiry unknown) due to provider ordering error, with no adverse event (Wrong Product administered) (Product administered to patient of inappropriate age) (Latency : Same day ) Information regarding batch number and expiration date corresponding to the one at tine of event occurrence was requested. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.